drugset / Trial / NCT03905304

Efficacy and Safety of MEDITOXIN® in Cervical Dystonia

NCT03905304

Phase 3 Completed 152 enrolled Medy-Tox
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to test the hypothesis that the efficacy and safety of Meditoxin® are not inferior to Botox®'s in the treatment of Cervical Dystonia.

Timeline

Start
2013-01-09
Primary completion
2014-07-30
Completion
2014-08-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 200 iu Intramuscular
Comparator Botulinum toxin type A Protein / enzyme biologic 300 iu Intramuscular

Indications